Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10314908

    Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation

    The United States of America as represented by the Secretary of the Department of · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10314790

    Sustained-release formulations of topiramate

    Supernus Pharmaceuticals, Inc. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10314810

    Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics

    Northwestern University · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10314819

    Solid state forms of Eluxadoline

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10314824

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Cumberland Pharmaceuticals Inc. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10314891

    Method for delivering pramlintide into a lumen of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10316038

    Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer

    Aclaris Therapeutics, Inc. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10314860

    Compositions and methods for treating and preventing venom related poisoning

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10316050

    PT (IV) complexes containing 4,4′-disubstituted-2,2′-bipyridyl and their use in cancer therapy

    THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10314840

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10316039

    P2X3 and/or P2X2/3 compounds and methods

    Asana BioSciences, LLC · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10316348

    Diagnostic system and process for rapid bacterial infection diagnosis

    Northwestern University · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10316080

    Protein-polymer-drug conjugates

    Asana BioSciences, LLC · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10314889

    Suppression of allergic lung inflammation and hyperreactivity

    The Regents of the University of California · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10316368

    Altered microbiome of chronic pelvic pain

    Northwestern University · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10314950

    Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications

    The Board of Regents of the University of Texas System · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10316289

    Methods of producing T memory stem cell populations

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10316031

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10316105

    Anti-TIE2 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10316316

    Compositions for targeted delivery of siRNA

    Arrowhead Pharmaceuticals, Inc. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10316318

    Oligonucleotide compositions and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10314904

    Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10314837

    Subcutaneous delivery of poly(oxazoline) polymer conjugates

    Serina Therapeutics, Inc. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10315984

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10316371

    Screening methods for identifying specific Staphylococcus aureus inhibitors

    TRANA DISCOVERY, INC. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10316073

    FCRN antagonists and methods of use

    The Board of Regents of the University of Texas System · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10316025

    Substituted piperazine compounds and methods of use and use thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. CA 3082337

    INHIBITEURS DE DOPAMINE-B-HYDROXYLASE

    BIAL PORTELA & CA SA [PT] · Granted Thu Jun 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10322171

    Vaccine with reduced enhancement of viral infection

    The Board of Regents of the University of Texas System · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10322213

    Compositions and methods for altering the rate of hydrolysis of cured oil-based materials

    ATRIUM MEDICAL CORPORATION · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10322069

    Restorative resin compositions and methods of use

    The Board of Regents of the University of Texas System · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10322094

    Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

    TONIX PHARMA LIMITED · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10322099

    Process to prepare treprostinil, the active ingredient in remodulin®

    United Therapeutics Corporation · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10321689

    Antimicrobial traditional Chinese medicine composition, and preparation method and use thereof

    INFINITUS (CHINA) COMPANY LTD. · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10322167

    Method of delivering gonadotropin releasing hormone or an analogue thereof into a lumen of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10322118

    Compounds and methods for inhibiting Cif virulence factor

    THE REGENTS OF TE UNIVERSITY OF CALIFORNIA · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10322125

    TGF-beta enhancing compositions for cartilage repair and methods related thereto

    The United States of America as represented by the Department of Veteran Affairs · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10322107

    N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor

    Nektar Therapeutics · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10322129

    Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions and methods for producing same

    O.D. Ocular Discovery Ltd. · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10322113

    Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same

    The Board of Regents of the University of Texas System · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10322095

    Endoxifen for local transdermal therapy to the breast

    Northwestern University · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10322124

    6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases

    Sulfateq B.V. · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10323027

    2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10322146

    Methods of conditioning patients for T cell therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10322181

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10322161

    EPHA4 cyclic peptide antagonists for neuroprotection and neural repair

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10322168

    High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same

    Amphastar Pharmaceuticals, Inc. · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10323061

    Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.